BRL-37344

{{Drugbox
 * IUPAC_name = 2-{{!(}}4-[(2R)-2-{{!(}}[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl]phenoxy}acetic acid
 * image = BRL-37344 Structure.svg


 * tradename = BRL-37344
 * legal_US = Investigational New Drug
 * legal_status =


 * bioavailability =
 * metabolism =
 * elimination_half-life =
 * excretion =


 * CAS_number = 114333-71-0
 * PubChem = 9841972
 * UNII = 5DZZ1926YW
 * ChemSpiderID = 2343
 * ChEMBL = 284782
 * ChEBI = 131180

}}
 * C=19 | H=22 | Cl=1 | N=1 | O=4
 * SMILES = C[C@H](CC1=CC=C(C=C1)OCC(=O)O)NC[C@@H](C2=CC(=CC=C2)Cl)O
 * StdInChI=1S/C19H22ClNO4/c1-13(21-11-18(22)15-3-2-4-16(20)10-15)9-14-5-7-17(8-6-14)25-12-19(23)24/h2-8,10,13,18,21-22H,9,11-12H2,1H3,(H,23,24)/t13-,18+/m1/s1
 * StdInChIKey = ZGGNJJJYUVRADP-ACJLOTCBSA-N

BRL-37344 is a drug which acts as a selective agonist of the β3 adrenergic receptor, which has been investigated for various biomedical research applications but never developed for clinical use.